These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 28035692)

  • 1. Application of a Risk Score to Identify Older Adults with Community-Onset Pneumonia Most Likely to Benefit From Empiric Pseudomonas Therapy.
    Frei CR; Rehani S; Lee GC; Boyd NK; Attia E; Pechal A; Britt RS; Mortensen EM
    Pharmacotherapy; 2017 Feb; 37(2):195-203. PubMed ID: 28035692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antipseudomonal monotherapy or combination therapy for older adults with community-onset pneumonia and multidrug-resistant risk factors: a retrospective cohort study.
    Obodozie-Ofoegbu OO; Teng C; Mortensen EM; Frei CR
    Am J Infect Control; 2019 Sep; 47(9):1053-1058. PubMed ID: 30904374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of inappropriate empiric antimicrobial therapy on outcome in Pseudomonas aeruginosa bacteraemia: a stratified analysis according to sites of infection.
    Joo EJ; Kang CI; Ha YE; Park SY; Kang SJ; Wi YM; Lee NY; Chung DR; Peck KR; Song JH
    Infection; 2011 Aug; 39(4):309-18. PubMed ID: 21594653
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia.
    Prina E; Ranzani OT; Polverino E; Cillóniz C; Ferrer M; Fernandez L; Puig de la Bellacasa J; Menéndez R; Mensa J; Torres A
    Ann Am Thorac Soc; 2015 Feb; 12(2):153-60. PubMed ID: 25521229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Community-acquired pneumonia with risk for drug-resistant pathogens.
    Fleming V; Buck B; Nix N; Kumar P; Southwood R
    South Med J; 2013 Mar; 106(3):209-16. PubMed ID: 23462490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community-Acquired Pneumonia Due to Multidrug- and Non-Multidrug-Resistant Pseudomonas aeruginosa.
    Cillóniz C; Gabarrús A; Ferrer M; Puig de la Bellacasa J; Rinaudo M; Mensa J; Niederman MS; Torres A
    Chest; 2016 Aug; 150(2):415-25. PubMed ID: 27060725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community-acquired Pseudomonas aeruginosa urinary tract infections in children hospitalized in a tertiary center: relative frequency, risk factors, antimicrobial resistance and treatment.
    Marcus N; Ashkenazi S; Samra Z; Cohen A; Livni G
    Infection; 2008 Oct; 36(5):421-6. PubMed ID: 18795227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis and Outcomes Associated With Inadequate and Broad-Spectrum Empiric Antibiotic Use.
    Rhee C; Kadri SS; Dekker JP; Danner RL; Chen HC; Fram D; Zhang F; Wang R; Klompas M;
    JAMA Netw Open; 2020 Apr; 3(4):e202899. PubMed ID: 32297949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of empiric antimicrobial therapy with a β-lactam and fluoroquinolone on mortality for patients hospitalized with severe pneumonia.
    Mortensen EM; Restrepo MI; Anzueto A; Pugh J
    Crit Care; 2005 Dec; 10(1):R8. PubMed ID: 16420641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of macrolide therapy in patients hospitalized with Pseudomonas aeruginosa community-acquired pneumonia.
    Laserna E; Sibila O; Fernandez JF; Maselli DJ; Mortensen EM; Anzueto A; Waterer G; Restrepo MI
    Chest; 2014 May; 145(5):1114-1120. PubMed ID: 24458223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new strategy for healthcare-associated pneumonia: a 2-year prospective multicenter cohort study using risk factors for multidrug-resistant pathogens to select initial empiric therapy.
    Maruyama T; Fujisawa T; Okuno M; Toyoshima H; Tsutsui K; Maeda H; Yuda H; Yoshida M; Kobayashi H; Taguchi O; Gabazza EC; Takei Y; Miyashita N; Ihara T; Brito V; Niederman MS
    Clin Infect Dis; 2013 Nov; 57(10):1373-83. PubMed ID: 23999080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudomonas aeruginosa nosocomial pneumonia: impact of pneumonia classification.
    Micek ST; Kollef MH; Torres A; Chen C; Rello J; Chastre J; Antonelli M; Welte T; Clair B; Ostermann H; Calbo E; Wunderink R; Menichetti F; Schramm G; Menon V
    Infect Control Hosp Epidemiol; 2015 Oct; 36(10):1190-7. PubMed ID: 26190444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for acquiring potentially drug-resistant pathogens in immunocompetent patients with pneumonia developed out of hospital.
    Jeong BH; Koh WJ; Yoo H; Park HY; Suh GY; Chung MP; Kwon OJ; Jeon K
    Respiration; 2014; 88(3):190-8. PubMed ID: 24994099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
    Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidelines-concordant empiric antimicrobial therapy and mortality in patients with severe community-acquired pneumonia requiring mechanical ventilation.
    Sakamoto Y; Yamauchi Y; Yasunaga H; Takeshima H; Hasegawa W; Jo T; Matsui H; Fushimi K; Nagase T
    Respir Investig; 2017 Jan; 55(1):39-44. PubMed ID: 28012492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors and antibiotic therapy in P. aeruginosa community-acquired pneumonia.
    Sibila O; Laserna E; Maselli DJ; Fernandez JF; Mortensen EM; Anzueto A; Waterer G; Restrepo MI
    Respirology; 2015 May; 20(4):660-6. PubMed ID: 25776134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre survey.
    Chen L; Zhou F; Li H; Xing X; Han X; Wang Y; Zhang C; Suo L; Wang J; Yu G; Wang G; Yao X; Yu H; Wang L; Liu M; Xue C; Liu B; Zhu X; Li Y; Xiao Y; Cui X; Li L; Uyeki TM; Wang C; Cao B;
    BMJ Open; 2018 Feb; 8(2):e018709. PubMed ID: 29449294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Guideline Recommendations for Dual Antipseudomonal Therapy in Hospitalized Adults with Pneumonia Using Combination Antibiograms.
    Luu Q; Vitale K; Shan G; Jayakumar R; Viswesh V
    Pharmacotherapy; 2020 Nov; 40(11):1089-1098. PubMed ID: 33037659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Predictors of drug-resistant pathogens in community-onset pneumonia: Are factors considered in health-care-associated pneumonia useful in the emergency department?].
    Torres Bonafonte OH; Gil Olivas E; Pérez Macho E; Pacho Pacho C; Mateo Roca M; Casademont Pou J; Ruiz Hidalgo D
    Emergencias; 2017 Oct; 29(5):306-312. PubMed ID: 29077289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensive care unit-acquired pneumonia due to Pseudomonas aeruginosa with and without multidrug resistance.
    Fernández-Barat L; Ferrer M; De Rosa F; Gabarrús A; Esperatti M; Terraneo S; Rinaudo M; Li Bassi G; Torres A
    J Infect; 2017 Feb; 74(2):142-152. PubMed ID: 27865895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.